Table 2 Agents used in the model overall and differentiated by model type
Abbreviation | Full name | Overall | Decision trees | Markov models | ISM | DES |
|---|---|---|---|---|---|---|
ABA | Abatacept | 13 | 12 | 0 | 1 | 0 |
ABA/MTX | Abatacept + Methotrexate | 11 | 0 | 0 | 10 | 1 |
ADA | Adalimumab | 29 | 20 | 3 | 2 | 4 |
ADA/MTX | Adalimumab + Methotrexate | 20 | 1 | 2 | 13 | 4 |
ANA | Anakinra | 1 | 1 | 0 | 0 | 0 |
ANA/MTX | Anakinra + Methotrexte | 9 | 1 | 0 | 0 | 8 |
AZA | Azathioprine | 48 | 0 | 8 | 0 | 40 |
BSC | Best Supportive Care | 47 | 0 | 1 | 18 | 28 |
BSC/MTX | Best Supportive Care + Methotrexate | 4 | 0 | 0 | 4 | 0 |
BUC | Bucillamine | 2 | 0 | 2 | 0 | 0 |
CEL | Celecoxib | 3 | 0 | 3 | 0 | 0 |
CER/MTX | Certolizumab + Methotrexate | 1 | 0 | 1 | 0 | 0 |
COR | Corticosteroid | 1 | 0 | 1 | 0 | 0 |
COX-2 | selective COX-2 inhibitor | 2 | 0 | 2 | 0 | 0 |
CYC | Ciclosporin | 60 | 0 | 9 | 11 | 40 |
CYC/MTX | Ciclosporin + Methotrexate | 35 | 1 | 0 | 0 | 34 |
DIC | Diclofenac | 1 | 0 | 1 | 0 | 0 |
DMARD | any Disease-Modifying-Anti-Rheumatic-Drug | 11 | 3 | 3 | 5 | 0 |
ETA | Etanercept | 48 | 26 | 7 | 3 | 12 |
ETA/MTX | Etanercept + Methotrexate | 18 | 2 | 3 | 9 | 4 |
ETO | Etoricoxib | 1 | 1 | 0 | 0 | 0 |
GOL/MTX | Golimumab + Methotrexate | 1 | 0 | 1 | 0 | 0 |
Gold | Â | 66 | 1 | 17 | 8 | 40 |
HCQ | Hydroxychloroquine | 12 | 0 | 0 | 0 | 12 |
HCQ/MTX | Hydroxychloroquine + Methotrexate | 20 | 1 | 8 | 0 | 11 |
IBU | Ibuprofen | 1 | 0 | 1 | 0 | 0 |
INF | Infliximab | 19 | 8 | 4 | 4 | 3 |
INF/MTX | Infliximab + Methotrexate | 36 | 1 | 8 | 11 | 16 |
LEF | Leflunomide | 66 | 1 | 16 | 9 | 40 |
LEF/MTX | Leflunomide + Methotrexate | 1 | 0 | 1 | 0 | 0 |
MTX | Methotrexate | 115 | 10 | 41 | 30 | 34 |
NAP | Naproxen | 2 | 1 | 1 | 0 | 0 |
NSAID | (nonselective) nonsteroidal anti-inflammatory drugs | 5 | 1 | 4 | 0 | 0 |
NSAID/H2RA | NSAID + H2 receptor antagonist | 1 | 1 | 0 | 0 | 0 |
NSAID/MIS | NSAID + Misoprostol | 2 | 1 | 1 | 0 | 0 |
NSAID/PPI | NSAID + proton pump inhibitor | 3 | 1 | 2 | 0 | 0 |
PEN | Penicillamine | 22 | 0 | 0 | 0 | 22 |
PRD/MTX | Prednisone/Prednisolone | 0 | 0 | 0 | 0 | 0 |
ROF | Rofecoxib | 1 | 0 | 1 | 0 | 0 |
RTX | Rituximab | 14 | 7 | 6 | 0 | 1 |
RTX/MTX | Rituximab + Methotrexate | 21 | 0 | 0 | 20 | 1 |
SUL | Sulfasalazine | 48 | 2 | 10 | 2 | 34 |
SUL/HCQ/MTX | Sulfasalazine + Hydroxychloroquine + Methotrexate | 14 | 1 | 2 | 0 | 11 |
SUL/MTX | Sulfasalazine + Hydroxychloroquine | 20 | 0 | 4 | 0 | 16 |
TNF | TNF-inhibitor | 14 | 1 | 9 | 2 | 2 |
TOC/MTX | Tocilizumab + Methotrexate | 3 | 0 | 0 | 3 | 0 |
OVERALL | Â | 872 | 106 | 183 | 165 | 418 |